Relationship between lncRNA-DUXAP9/DUXAP10 expression and clinical prognosis of hepatocellular carcinoma patients after hepatectomy

doi:10.3877/cma.j.issn.2095-3232.2020.06.021

Abstract

Abstract:

Objective

To explore the relationship between the expression level of long non-coding RNA (lncRNA)-DUXAP9/DUXAP10 and clinical prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy.

Methods

The specimens were collected from 63 HCC patients who underwent hepatectomy in Xuyi People's Hospital from January 2012 to December 2015. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 35 patients were male and 28 female, aged 20-70 years, with a median age of 52 years. The abnormally-expressed genes were screened by lncRNAs microarray. The mRNA expression levels were detected by real-time fluorescence quantitative PCR. Survival curve was delineated by Kaplan-Meier survival curve. Survival analysis was conducted by Log-rank test. The prognostic factors of HCC patients after hepatectomy were identified by Cox's proportional hazard regression model.

Results

The lncRNAs microarray showed that 256 lncRNAs expressed abnormally, expression of 162 lncRNAs were up-regulated and 94 were down-regulated. Two abnormally-expressed genes, lncRNA-DUXAP9 and lncRNA-DUXAP10, were further screened (fold change=6.35, 4.53; P<0.05). Survival analysis demonstrated that the expression of lncRNA-DUXAP9/DUXAP10 was significantly correlated with the overall survival and tumor-free survival of HCC patients after hepatectomy (χ²=1.817, 1.693 and 2.163, 1.961; P<0.05). Cox's proportional hazard regression model indicated that the expression levels of lncRNA-DUXAP9/DUXAP10 were the independent risk factors for clinical prognosis of HCC patients after hepatectomy (HR=2.524, 1.316; P<0.05).

Conclusions

lncRNA-DUXAP9/DUXAP10 are highly expressed in HCC patients, which are the independent risk factors for clinical prognosis of HCC patients undergoing hepatectomy.

Key words: Long non-coding RNA, DUXAP, Carcinoma, hepatocellular, Hepatectomy, Prognosis

Qian Zhu, Chao Shi, Jingyao Shen, Liang Xu, Jie Ying, Liping Hu. Relationship between lncRNA-DUXAP9/DUXAP10 expression and clinical prognosis of hepatocellular carcinoma patients after hepatectomy[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(06): 596-601.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2020.06.021

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2020/V09/I06/596

Figures/Tables 4

References 25

[1]	Han Li C, Chen Y. Small and long non-coding RNAs: novel targets in perspective cancer therapy[J]. Curr Genomics, 2015, 16(5):319-326.
[2]	Morceau F, Chateauvieux S, Gaigneaux A, et al. Long and short non-coding RNAs as regulators of hematopoietic differentiation[J]. Int J Mol Sci, 2013, 14(7):14744-14770.
[3]	Uchida S, Bolli R. Short and long noncoding RNAs regulate the epigenetic status of cells[J]. Antioxid Redox Signal, 2018, 29(9):832-845.
[4]	Chen M, Zhuang C, Liu Y, et al. Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer[J]. Cancer Lett, 2016, 376(1):155-164.
[5]	Yao Y, Ma J, Xue Y, et al. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152[J]. Cancer Lett, 2015, 359(38): 75-86.
[6]	Wang D, Ding L, Wang L, et al. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer[J]. Oncotarget, 2015, 6(38):41045-41055.
[7]	Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in cancer:current status and future perspectives[J]. Mol Cancer, 2016, 15(1):39.
[8]	Li C, Chen J, Zhang K, et al. Progress and prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma[J]. Cell Physiol Biochem, 2015, 36(2):423-434.
[9]	Wang F, Ying HQ, He BS, et al. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway[J]. Oncotarget, 2015, 6(10):7899-7917.
[10]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[11]	Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009[J]. Lancet Oncol, 2009, 10(11):1111-1118.
[12]	Hefaiedh R, Sabbeh M, Ennaifer R, et al. Percutaneous treatment versus hepatic resection for the treatment of small hepatocellular carcinoma[J]. Tunis Med, 2015, 93(3):132-137.
[13]	Murata S, Mine T, Sugihara F, et al. Interventional treatment for unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(37):13453-13465.
[14]	Hao S, Fan P, Chen S, et al. Distinct recurrence risk factors for intrahepatic metastasis and multicenter occurrence after surgery in patients with hepatocellular carcinoma[J]. J Gastrointest Surg, 2017, 21(12):312-320.
[15]	Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review[J]. Hepatol Int, 2008, 2(1):17-30.
[16]	Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma[J]. Ann Surg, 2009, 249(5):799-805.
[17]	Liu Z, Li X, Sun N, et al. Microarray profiling and co-expression network analysis of circulating lncRNAs and mRNAs associated with major depressive disorder[J]. PLoS One, 2014, 9(3):e93388.
[18]	Leidenroth A, Hewitt JE. A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene[J]. BMC Evol Biol, 2010(10):364.
[19]	Eidahl JO, Giesige CR, Domire JS, et al. Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4[J]. Hum Mol Genet, 2016, 25(20):4577-4589.
[20]	Töhönen V, Katayama S, Vesterlund L, et al. Novel PRD-like homeodomain transcription factors and retrotransposon elements in early human development[J]. Nat Commun, 2015(6):8207.
[21]	Booth HA, Holland PW. Annotation, nomenclature and evolution of four novel homeobox genes expressed in the human germ line[J]. Gene, 2007, 387(1/2):7-14.
[22]	Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs[J]. Nature, 2013, 500(7464):598-602.
[23]	Zhou X, Ye F, Yin C, et al. The interaction between MiR-141 and lncRNA-H19 in regulating cell proliferation and migration in gastric cancer[J]. Cell Physiol Biochem, 2015, 36(4):1440-1452.
[24]	Wang Y, Gao S, Liu G, et al. Microarray expression profile analysis of long non-coding RNAs in human gastric cardiac adenocarcinoma[J]. Cell Physiol Biochem, 2014, 33(4):1225-1238.
[25]	Tang Q, Ni Z, Cheng Z, et al. Three circulating long non-coding RNAs act as biomarkers for predicting NSCLC[J]. Cell Physiol Biochem, 2015, 37(3):1002-1009.

变量	单因素分析			多因素分析
变量	HR	95%CI	P值	HR	95%CI	P值
AFP	1.629	1.372～3.581	0.008	0.946	0.649～1.302	0.782
TNM分期	1.542	1.293～2.735	0.026	1.105	0.756～1.291	0.337
肿瘤数目	1.593	1.184～3.024	0.031	1.059	0.921～1.491	0.192
肿瘤直径	1.583	1.216～2.663	0.012	1.377	1.243～2.582	0.026
微血管侵犯	1.864	1.392～3.261	0.003	1.402	1.143～3.633	0.014
lncRNA-DUXAP9	1.905	1.482～2.693	0.001	2.524	1.661～4.015	0.001
lncRNA-DUXAP10	1.826	1.265～3.254	0.008	1.316	1.251～2.619	0.036

变量	单因素分析			多因素分析
变量	HR	95%CI	P值	HR	95%CI	P值
AFP	1.629	1.372～3.581	0.008	0.946	0.649～1.302	0.782
TNM分期	1.542	1.293～2.735	0.026	1.105	0.756～1.291	0.337
肿瘤数目	1.593	1.184～3.024	0.031	1.059	0.921～1.491	0.192
肿瘤直径	1.583	1.216～2.663	0.012	1.377	1.243～2.582	0.026
微血管侵犯	1.864	1.392～3.261	0.003	1.402	1.143～3.633	0.014
lncRNA-DUXAP9	1.905	1.482～2.693	0.001	2.524	1.661～4.015	0.001
lncRNA-DUXAP10	1.826	1.265～3.254	0.008	1.316	1.251～2.619	0.036

Please choose a citation manager

Content to export